This website is intended for US Healthcare Professionals.


An investigational, oral PROTAC® androgen receptor (AR) degrader.

ARV-766 is currently under investigation. Its safety and effectiveness have not been established.

Clinical Trial Information

Phase 1/2
ARV-766 alone or in combination with abiraterone in previously treated metastatic prostate cancer

Related Links

ARV-766 Congress Presentations

Access materials related to ARV-766 presentations at scientific congresses.

ARV-766 Publications

View Arvinas publications about ARV-766.

Contact My MSL

Connect with your Medical Science Liaison (MSL).

Arvinas Oncology Medical

You are now leaving Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Arvinas Oncology Medical

This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.

By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).

If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to